Gastrointestinal motility disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:31:29 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Gastrointestinal motility disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Naloxegol to Prevent Constipation in Patients with Brain Injury and Opioid Use https://clinicaltrials.eu/trial/study-on-naloxegol-to-prevent-constipation-in-patients-with-brain-injury-and-opioid-use/ Wed, 29 Apr 2026 14:27:46 +0000 https://clinicaltrials.eu/trial/study-on-naloxegol-to-prevent-constipation-in-patients-with-brain-injury-and-opioid-use/ This clinical trial is focused on patients who have experienced head trauma or a type of bleeding in the brain known as meningeal hemorrhage. These conditions can lead to problems with the movement of food through the digestive system, known as gastrointestinal motility disorders. The study is investigating the use of a medication called Moventig, which contains the active ingredient naloxegol oxalate. This medication is being tested to see if it can help prevent constipation and lung infections in patients who are receiving strong pain medications, known as opioids, while in intensive care.

The purpose of the study is to evaluate how effective naloxegol is in preventing early constipation and lung infections in patients with brain injuries who are being treated with opioids. Participants in the study will receive either the medication or a placebo, which looks like the medication but does not contain the active ingredient. The study will follow patients to see if they experience any bowel movements or lung infections during their hospital stay.

Throughout the study, researchers will monitor various aspects of the patients’ health, such as their ability to meet nutritional goals, the need for additional medications to manage vomiting or constipation, and the length of time they require mechanical ventilation. The study will also track the overall recovery of patients over a period of six months, using a scale called the Glasgow Outcome Scale Extended (GOSE), which measures recovery after brain injury. The study is expected to continue until September 2026.

]]> Study on the Effects of Buspirone Hydrochloride for Patients with Weak or Absent Esophageal Motility https://clinicaltrials.eu/trial/study-on-the-effects-of-buspirone-hydrochloride-for-patients-with-weak-or-absent-esophageal-motility/ Wed, 29 Apr 2026 14:22:43 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-buspirone-hydrochloride-for-patients-with-weak-or-absent-esophageal-motility/ This clinical trial is focused on studying the effects of a medication called Buspirone hydrochloride on individuals experiencing difficulties with swallowing due to weak or absent muscle movements in the esophagus, a condition known as dysphagia. The esophagus is the tube that carries food from the mouth to the stomach, and in some people, it doesn’t move food effectively, leading to swallowing problems. The study aims to understand how Buspirone hydrochloride, which is taken as a tablet, can help improve the movement of the esophagus and ease symptoms of dysphagia.

Participants in the study will receive either the Buspirone hydrochloride tablet or a placebo tablet, which looks like the medication but does not contain the active drug. The study is designed to compare the effects of the actual medication with the placebo to see if there is a significant improvement in esophageal movement and swallowing symptoms. The trial will use a special test called high-resolution esophageal manometry, which measures the pressure and movement inside the esophagus, to assess the effects of the treatment.

The study will take place over a period of time, during which participants will undergo several assessments to monitor changes in their condition. The goal is to determine if Buspirone hydrochloride can be an effective treatment for improving esophageal motility and reducing the symptoms of dysphagia. This research could potentially lead to better management options for individuals suffering from this condition.

]]>